Mono Clinical Trials

172 recruitingLast updated: July 25, 2026

There are 172 actively recruiting mono clinical trials across 37 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Seattle, Washington, United States. Updated daily from ClinicalTrials.gov.


Mono Trials at a Glance

172 actively recruiting trials for mono are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 2 with 66 trials, with the heaviest enrollment activity in Houston, Boston, and Seattle. Lead sponsors running mono studies include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, and Mayo Clinic.

Treatments under study

About Mono Clinical Trials

Looking for clinical trials for Mono? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mono trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mono clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 172 trials

Recruiting
Phase 2

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+1 more
Fred Hutchinson Cancer Center20 enrolled1 locationNCT07046078
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Not Applicable

Evaluating How Well Different Types of Light-sensitive Cells in the Eye Contribute to Its Focusing Ability

MonochromaticL- and S-cone Modulation OnlyL- and M-cone Modulation Only+1 more
Rochester Institute of Technology20 enrolled1 locationNCT07691463
Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Phase 1Phase 2

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)Myelofibrosis (MF)
M.D. Anderson Cancer Center66 enrolled1 locationNCT07128381
Recruiting

Study of Factors Regulating Mast Cell Proliferation

MastocytosisMonoclonalBone Marrow+1 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00044122
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting

Pre-malignant States to Hematologic Malignancies in Firefighters

Non-Hodgkin LymphomaMultiple MyelomaLeukemia+3 more
Wake Forest University Health Sciences300 enrolled1 locationNCT06870760
Recruiting
Not Applicable

The Effects of Exogenous Ketones on Cognitive Function

Placebo - ControlKetone Monoester
University of Alabama at Birmingham45 enrolled1 locationNCT07051655
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled39 locationsNCT06140524
Recruiting
Not Applicable

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
Children's Hospital of Philadelphia50 enrolled1 locationNCT03810196
Recruiting
Phase 2

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
M.D. Anderson Cancer Center15 enrolled2 locationsNCT06566742
Recruiting
Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)+2 more
AstraZeneca257 enrolled97 locationsNCT06535607
Recruiting
Phase 2

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Not Applicable

Halt Aging in Survivors of Blood Cancers

Non-Hodgkin LymphomaMultiple MyelomaLeukemia+5 more
University of Nebraska180 enrolled1 locationNCT07292272
Recruiting
Phase 2

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+3 more
City of Hope Medical Center35 enrolled1 locationNCT06815003
Recruiting
Phase 2

Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer

Short-course Radiotherapy Plus ChemotherapyNodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab
Dechang Diao76 enrolled1 locationNCT07674732
Recruiting
Phase 2

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+25 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 1

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Chronic Myelomonocytic Leukemia
Huda Salman30 enrolled4 locationsNCT06071624
Recruiting

A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity

Monogenic Obesity
Assistance Publique - Hôpitaux de Paris175 enrolled2 locationsNCT06380426